Stockscreener 앱 받기
44.09
1.76%
-0.79
전일 마감가:
$44.88
열려 있는:
$44.54
하루 거래량:
340.24K
Relative Volume:
0.43
시가총액:
$2.16B
수익:
$140.49M
순이익/손실:
$-153.49M
주가수익비율:
-16.00
EPS:
-2.7551
순현금흐름:
$-175.90M
1주 성능:
+1.08%
1개월 성능:
+10.45%
6개월 성능:
+118.70%
1년 성능:
+134.52%
1일 변동 폭
$43.50
$45.09
1주일 범위
$42.00
$45.88
52주 변동 폭
$15.86
$50.81
Urogen Pharma Ltd Stock (URGN) Company Profile
명칭
Urogen Pharma Ltd
전화
972 9 770 7601
주소
9 HA'TA'ASIYA ST, RA'ANANA
Compare URGN vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
URGN
Urogen Pharma Ltd
|
44.09 | 2.29B | 140.49M | -153.49M | -175.90M | -2.7551 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-10 | 개시 | Jefferies | Buy |
| 2025-08-19 | 개시 | Piper Sandler | Overweight |
| 2025-06-16 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-05-22 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-04-16 | 개시 | Scotiabank | Sector Outperform |
| 2025-02-19 | 재개 | Ladenburg Thalmann | Buy |
| 2024-08-22 | 개시 | Guggenheim | Buy |
| 2023-02-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-04-27 | 개시 | Berenberg | Buy |
| 2020-04-16 | 재확인 | H.C. Wainwright | Buy |
| 2020-04-13 | 재확인 | H.C. Wainwright | Buy |
| 2020-01-09 | 개시 | National Securities | Neutral |
| 2019-05-30 | 개시 | JP Morgan | Neutral |
| 2019-05-29 | 개시 | Goldman | Neutral |
| 2019-01-29 | 개시 | H.C. Wainwright | Buy |
| 2018-11-08 | 재개 | Jefferies | Buy |
| 2018-04-04 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2018-01-02 | 개시 | Ladenburg Thalmann | Buy |
| 2017-11-15 | 재확인 | Oppenheimer | Outperform |
| 2017-11-15 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
모두보기
Urogen Pharma Ltd 주식(URGN)의 최신 뉴스
UGN-103 NDA Filing for Recurrent Bladder Cancer Might Change The Case For Investing In UroGen Pharma (URGN) - simplywall.st
UroGen Pharma inks licensing deal with IntraGel Therapeutics - The Pharma Letter
UroGen Pharma Enters Option and Investment Deal with IntraGel Therapeutics - Kalkine Media
UroGen (NASDAQ: URGN) officer sold $750K in stock, plans more - Stock Titan
Cancer treatment co UroGen invests $7m in Israel’s IntraGelGlobes - Globes - Israel Business News
INTRAGEL THERAPEUTICS LTD announced that it expects to receive $7 million in funding from UroGen Pharma Ltd. - marketscreener.com
UroGen Pharma secures option deal with IntraGel for cancer tech By Investing.com - Investing.com Nigeria
IntraGel secures $7M from UroGen for cancer therapy development By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates UroGen Pharma stock rating on NDA filing By Investing.com - Investing.com Canada
UroGen Signs Investment, Collaboration Agreements With IntraGel for Access to Sustained-Release Platform - marketscreener.com
URGN Looks 90.6% Overvalued on GF Value™ - GuruFocus
UroGen inks equity and option deals with IntraGel (URGN:NASDAQ) - Seeking Alpha
UroGen Pharma secures option to license IntraGel SRGel program, agrees up to $7M investment - TradingView
UroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology Pipeline - The Manila Times
IntraGel's head and neck cancer drug study gets up to $7 million for Phase 2 - Stock Titan
UroGen gets an exclusive option on TumoCure after Phase 2 - Stock Titan
Urogen Pharma stock hits 52-week high at 49.69 USD By Investing.com - Investing.com South Africa
Urogen Pharma (NASDAQ:URGN) Reaches New 1-Year HighHere's What Happened - MarketBeat
Urogen Pharma stock hits 52-week high at 49.69 USD - Investing.com
UroGen Submits NDA for UGN-103, an Investigational Treatment of Recurrent LG-IR-NMIBC - Sahm
Rice Hall James & Associates LLC Purchases Shares of 300,650 Urogen Pharma $URGN - MarketBeat
The Manufacturers Life Insurance Company Has $196,000 Stock Holdings in Urogen Pharma $URGN - MarketBeat
UroGen Pharma Submits US FDA New Drug Application for UGN-103 in Recurrent Bladder Cancer - marketscreener.com
UroGen submits FDA application for bladder cancer drug UGN-103 By Investing.com - Investing.com India
URGN Looks 84.5% Overvalued on GF Value™ - GuruFocus
UroGen submits FDA application for bladder cancer drug UGN-103 - Investing.com
Ninety-nine patients entered a bladder cancer trial—what came next? - Stock Titan
California State Teachers Retirement System Grows Stock Holdings in Urogen Pharma $URGN - MarketBeat
Is UroGen Pharma (URGN) Overvalued As Sales Growth And Patent Clarity Lift Confidence? - simplywall.st
Are You Looking for a Top Momentum Pick? Why Urogen Pharma (URGN) is a Great Choice - Yahoo Finance
UroGen Pharma Ltd (URGN) Competitors 2026 - GuruFocus
(URGN) Volatility Zones as Tactical Triggers - Stock Traders Daily
UroGen (URGN) Q2 2026 Earnings Call Transcript - AOL.com
UroGen Pharma (URGN): TD Bank group discloses 3.37M shares, 6.9% beneficial stake - Stock Titan
Urogen Pharma (NASDAQ:URGN) Hits New 1-Year HighTime to Buy? - MarketBeat
UroGen Pharma (URGN) Is Up 21.7% After Q2 Revenue Triples And Loss Narrows Has The Bull Case Changed? - Sahm
Urogen Pharma Ltd at TD Cowen Healthcare Conference Transcript - GuruFocus
URGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
UroGen Pharma Ltd. (URGN) Options Chain - Yahoo! Finance Canada
Q3 EPS Estimates for Urogen Pharma Lifted by HC Wainwright - MarketBeat
UroGen Pharma (URGN) Stock Looks Fairly Priced Despite Its 210% Run - Sahm
UroGen Pharma (URGN) Earnings Put Its Fair Value Debate Back In Focus - Yahoo Finance
Why UroGen Pharma (URGN) Is Up 22.8% After Q2 2026 Revenue Nearly Tripled And Losses Narrowed - Yahoo Finance
Urogen Pharma $URGN Shares Purchased by Hennion & Walsh Asset Management Inc. - MarketBeat
UroGen Pharma Ltd. Revenue Breakdown – MUN:UR8 - TradingView
UroGen Pharma Ltd (NASDAQ: URGN) Share Price, URGN Stock News, URGN Share Price & Updates - Kalkine
Bullish: Analysts Just Made An Incredible Upgrade To Their UroGen Pharma Ltd. (NASDAQ:URGN) Forecasts - simplywall.st
Oppenheimer Adjusts PT on UroGen Pharma to $60 From $50, Maintains Outperform Rating - Moomoo
Oppenheimer Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Raises Target Price to $60 - 富途牛牛
Guggenheim raises UroGen Pharma stock price target to $58 on sales beat - Investing.com South Africa
A Quick Look at Today's Ratings for UroGen Pharma Ltd(URGN.US), With a Forecast Between $48 to $75 - 富途牛牛
Urogen Pharma Ltd (URGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.86%
0.31%
자본화:
|
볼륨(24시간):